NAT10 and cancer: Previously, we discovered that Remodelin, the only known small molecule inhibitor of NAT10, alters lipid metabolic pathways in cancer cells, which include fatty acid elongation in mitochondria, fatty acid metabolism, and mitochondrial beta-oxidation of saturated fatty acids [20].